ORPHENADRINE CITRATE tablet, extended release
Orphenadrine Citrate by
Drug Labeling and Warnings
Orphenadrine Citrate by is a Prescription medication manufactured, distributed, or labeled by Woodward Pharma Services LLC. Drug facts, warnings, and ingredients follow.
Drug Details [pdf]
- SPL UNCLASSIFIED SECTION
-
DESCRIPTION:
Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethyl-aminoethyl 2-methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol and has a molecular weight of 461.51. The molecular formula C 18H 23NOC 6H 8O 7 is represented by the following structural formula:
Each orphenadrine citrate extended-release tablet contains 100 mg orphenadrine citrate, USP. Orphenadrine citrate extended-release tablets also contain: calcium stearate, ethylcellulose, and lactose monohydrate.
- CLINICAL PHARMACOLOGY:
- INDICATIONS AND USAGE:
-
CONTRAINDICATIONS:
Contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (megaesophagus) and myasthenia gravis.
Contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.
-
WARNINGS:
Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine citrate may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
-
PRECAUTIONS
Confusion, anxiety and tremors have been reported in few patients receiving propoxyphene and orphenadrine concomitantly. As these symptoms may be simply due to an additive effect, reduction of dosage and/or discontinuation of one or both agents is recommended in such cases.
Orphenadrine citrate should be used with caution in patients with tachycardia, cardiac decompensation, coronary insufficiency, cardiac arrhythmias.
Safety of continuous long-term therapy with orphenadrine citrate has not been established. Therefore, if orphenadrine citrate is prescribed for prolonged use, periodic monitoring of blood, urine and liver function values is recommended.
-
PREGNANCY
Pregnancy Category C
Animal reproduction studies have not been conducted with orphenadrine citrate. It is also not known whether orphenadrine citrate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine citrate should be given to a pregnant woman only if clearly needed.
- PEDIATRIC USE
-
ADVERSE REACTIONS:
Adverse reactions of orphenadrine citrate are mainly due to the mild anti-cholinergic action of orphenadrine citrate and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.
- DRUG ABUSE AND DEPENDENCE
-
OVERDOSAGE
Orphenadrine citrate is toxic when overdosed and typically induces anti-cholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine citrate overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring and appropriate supportive treatment of any emergent anti-cholinergic effects.
- DOSAGE AND ADMINISTRATION:
-
HOW SUPPLIED:
Orphenadrine Citrate Extended-Release Tablets, for oral administration, are available as
100 mg
White to off-white, round tablets debossed 'CL 71' on one side and plain on the other side and supplied as:
NDC: 69784-905-01 bottles of 100
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure.
KEEP TIGHTLY CLOSED.
To report SUSPECTED ADVERSE REACTIONS, contact Woodward Pharma Services LLC at 1-888-514-4727 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Manufactured for:
Woodward Pharma Services LLC
Birmingham, MI 48009
Rev. 09/2017 A
- PRINCIPAL DISPLAY PANEL
-
INGREDIENTS AND APPEARANCE
ORPHENADRINE CITRATE
orphenadrine citrate tablet, extended releaseProduct Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC: 69784-905 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength ORPHENADRINE CITRATE (UNII: X0A40N8I4S) (ORPHENADRINE - UNII:AL805O9OG9) ORPHENADRINE CITRATE 100 mg Product Characteristics Color white Score no score Shape ROUND Size 9mm Flavor Imprint Code CL71 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 69784-905-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 06/28/2017 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040249 05/26/2017 Labeler - Woodward Pharma Services LLC (026749066)
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.